{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:33:00Z","timestamp":1777566780864,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,5]],"date-time":"2021-09-05T00:00:00Z","timestamp":1630800000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoporosis and Sarcopenia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.afos.2021.09.002","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T08:35:13Z","timestamp":1631176513000},"page":"89-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Romosozumab and cardiovascular safety in Japan"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-5233","authenticated-orcid":false,"given":"Yasuhiro","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.afos.2021.09.002_bib1","first-page":"785","article-title":"NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.afos.2021.09.002_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1359\/JBMR.041114","article-title":"Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling","volume":"20","author":"Riggs","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2021.09.002_bib3","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2021.09.002_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00774-020-01176-0","article-title":"Sclerostin: from bench to bedside","volume":"39","author":"Tanaka","year":"2021","journal-title":"J\u00a0Bone Miner Metabol"},{"key":"10.1016\/j.afos.2021.09.002_bib5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.afos.2021.09.002_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","article-title":"Sclerostin deficiency in humans","volume":"96","author":"van Lierop","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.afos.2021.09.002_bib7","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.afos.2021.09.002_bib8","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1210\/clinem\/dgab193","article-title":"Cardiovascular safety and sclerostin Inhibition","volume":"106","author":"Langdahl","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2021.09.002_bib9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1161\/ATVBAHA.119.312371","article-title":"Cardiovascular outcomes of romosozumab and protective role of alendronate","volume":"39","author":"Asadipooya","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.afos.2021.09.002_bib10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1126\/science.1136370","article-title":"LRP6 mutation in a family with early coronary disease and metabolic risk factors","volume":"315","author":"Mani","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.afos.2021.09.002_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay6570","article-title":"Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics","volume":"12","author":"Bovijn","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.afos.2021.09.002_bib12","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/jbmr.4287","article-title":"Sclerostin downregulation globally by naturally occurring genetic variants, or locally in atherosclerotic plaques, does not associate with cardiovascular events in humans","volume":"36","author":"Holdsworth","year":"2021","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2021.09.002_bib13","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/jbmr.3448","article-title":"Association of alendronate and risk of cardiovascular events in patients with hip fracture","volume":"33","author":"Sing","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2021.09.002_bib14","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa481","article-title":"Oral bisphosphonate use reduces cardiovascular events in a cohort of Danish patients referred for bone mineral density","volume":"105","author":"Rodr\u00edguez","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2021.09.002_bib15","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2008.11.037","article-title":"Relation of bisphosphonate therapies and risk of developing atrial fibrillation","volume":"103","author":"Bunch","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.afos.2021.09.002_bib16","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jamainternmed.2019.2779","article-title":"Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis","volume":"179","author":"Cummings","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.afos.2021.09.002_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","article-title":"Japanese society for bone and mineral research and Japan osteoporosis society joint review committee for the revision of the diagnostic criteria for primary osteoporosis. Diagnostic criteria for primary osteoporosis: year 2012 revision","volume":"31","author":"Soen","year":"2013","journal-title":"J\u00a0Bone Miner Metabol"},{"key":"10.1016\/j.afos.2021.09.002_bib18","series-title":"Results of the post-marketing survey of Evenity","author":"Astellas Pharma","year":"2020"},{"key":"10.1016\/j.afos.2021.09.002_bib19","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1253\/circj.CJ-17-0177","article-title":"Incidence, management and short-term outcome of stroke in a general population of 1.4 million Japanese- Shiga stroke registry","volume":"81","author":"Takashima","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.afos.2021.09.002_bib20","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/aje\/kwn064","article-title":"Trend of increase in the incidence of acute myocardial infarction in a Japanese population: Takashima AMI Registry, 1990\u20132001","volume":"167","author":"Rumana","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.afos.2021.09.002_bib21","first-page":"1660","article-title":"Burden AM. Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food and drug administration adverse event reporting System (FAERS)","volume":"10","author":"Kvist","year":"2021","journal-title":"J\u00a0Clin Med"}],"container-title":["Osteoporosis and Sarcopenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525521000613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525521000613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:35:02Z","timestamp":1762500902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405525521000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2405525521000613"],"URL":"https:\/\/doi.org\/10.1016\/j.afos.2021.09.002","relation":{},"ISSN":["2405-5255"],"issn-type":[{"value":"2405-5255","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Romosozumab and cardiovascular safety in Japan","name":"articletitle","label":"Article Title"},{"value":"Osteoporosis and Sarcopenia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.afos.2021.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}